The Case Comprehensive Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1826-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.case.edu/cancer
Clinical Trials
470
Active:22
Completed:241
Trial Phases
6 Phases
Early Phase 1:26
Phase 1:74
Phase 2:128
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (412 trials with phase data)• Click on a phase to view related trials
Not Applicable
171 (41.5%)Phase 2
128 (31.1%)Phase 1
74 (18.0%)Early Phase 1
26 (6.3%)Phase 3
12 (2.9%)Phase 4
1 (0.2%)Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma
Not Applicable
Not yet recruiting
- Conditions
- Human Papilloma Virus Related CarcinomaTonsillar Squamous Cell Carcinoma
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT07060261
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio, United States
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
Not Applicable
Not yet recruiting
- Conditions
- Colorectal CancerLiver MetastasesLiver Cancer
- Interventions
- Device: HistoSonics Edison® SystemDrug: Chemotherapy
- First Posted Date
- 2025-06-30
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT07044362
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Improving Patient Understanding of Their Prostate Cancer Diagnosis Using AI
Not Applicable
Not yet recruiting
- Conditions
- Prostate Cancer
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT07040501
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, Cleveland Clinic Glickman Urologic Institute, Cleveland, Ohio, United States
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT07003542
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio, United States
Herbs & Supplements in Breast Cancer Usage, Impact, and Personalized Approaches for Diverse Populations
Not yet recruiting
- Conditions
- Breast CancerBreast Cancer Stage IIBreast Cancer Stage IBreast Cancer Stage IIIBreast Carcinoma
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 240
- Registration Number
- NCT06926530
- Locations
- 🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States
🇺🇸Cleveland Clinic Main Campus, Cleveland, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 94
- Next
News
No news found